대원제약 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 임한일, was filed 13 Mar 2026.
대원제약: what insiders have been doing
This page follows insider dealings at 대원제약 as filed with DART (FSS), a company from the Health Care sector. In the past year (1 November 2025 to 1 November 2026), 2 filings came from 1 insider.
The record shows 1 purchase on the open market worth €18k, made by 1 insider, against 1 sale by 1 insider. The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 senior executive. At €18k, the purchase published on 13 March 2026 by 임한일 is the largest of the period (0.018% of market cap).
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 2 filings here. The full history, which starts in 2021, counts 11 purchases against 2 sales.
The most recent open-market purchase was published on 13 March 2026, 242 days ago.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -19.9%Entry ₩10,840 · Close 30 Oct 2026 ₩8,680
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate 대원제약 Strong Buy (bullish), based on 3 analysts. Average price target: ₩14,667.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 15,000 sharesShareKRXDART:20260610000620
- 3,000 shares@ ₩10,259.500.018% mcap100.0% of flowShareKRXDART:20260313001181Canonical exit: 9 Jun 2026 (T+90)
- 708 sharesShareKRXDART:20250107000306Canonical exit: 7 Apr 2025 (T+90)
- ShareKRXDART:20240906000610Canonical exit: 4 Dec 2024 (T+90)
- 113,090 sharesKRXDART:20240816000165Canonical exit: 11 Nov 2024 (T+90)
- ShareKRXDART:20240722000245
- ShareKRXDART:20240513000780
- 113,090 sharesKRXDART:20231221000522Canonical exit: 20 Mar 2024 (T+90)
- 113,090 sharesKRXDART:20230704000487Canonical exit: 2 Oct 2023 (T+90)
- ShareKRXDART:20230704000507
- ShareKRXDART:20230704000503
- ShareKRXDART:20230704000499
- ShareKRXDART:20230704000497
- ShareKRXDART:20220928000034
- ShareKRXDART:20220915000193
- ShareKRXDART:20220902000039
- ShareKRXDART:20220610000453
- 255 sharesShareKRXDART:20220310001239Canonical exit: 6 Jun 2022 (T+90)
- 4,523 sharesShareKRXDART:20220310001241Canonical exit: 6 Jun 2022 (T+90)
- 23,347 sharesShareKRXDART:20220310001244Canonical exit: 6 Jun 2022 (T+90)
- 14 sharesShareKRXDART:20220310001229Canonical exit: 6 Jun 2022 (T+90)
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
25 of 60 declarations
About 대원제약
Daewon Pharmaceutical is a South Korean company operating in the healthcare and pharmaceutical sector. It is listed on the XKRX.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
